^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI-1808

    i
    Other names: BI-1808
    Associations

    News

    Trials
    Company:
    BioInvent
    Drug class:
    TNFRSF1B ligand blocker
    Associations

    News

    Trials
    1year
    BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) (clinicaltrials.gov)
    P1/2, N=176, Recruiting, BioInvent International AB | N=100 --> 176
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • BI-1808
    1year
    BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) (clinicaltrials.gov)
    P1/2, N=100, Recruiting, BioInvent International AB | Trial completion date: Dec 2026 --> Jan 2028 | Trial primary completion date: May 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • BI-1808
    over2years
    BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) (clinicaltrials.gov)
    P1/2, N=100, Recruiting, BioInvent International AB | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD14 (CD14 Molecule)
    |
    Keytruda (pembrolizumab) • BI-1808
    5years
    BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, BioInvent International AB
    Clinical • New P1/2 trial • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD14 (CD14 Molecule)
    |
    Keytruda (pembrolizumab) • BI-1808
    over5years
    [VIRTUAL] Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy (SITC 2020)
    Conclusions There is a clear association between RO and therapeutic effect and BI-1808 is well tolerated at doses associated with high and sustained RO. Collectively, these studies were used to determine the starting dose in upcoming phase I/II study in solid cancer aiming for first-patient in during December 2020.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • FCGR2A (Fc fragment of IgG receptor IIa)
    |
    BI-1808
    over5years
    [VIRTUAL] Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy (SITC 2020)
    Conclusions There is a clear association between RO and therapeutic effect and BI-1808 is well tolerated at doses associated with high and sustained RO. Collectively, these studies were used to determine the starting dose in upcoming phase I/II study in solid cancer aiming for first-patient in during December 2020.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • FCGR2A (Fc fragment of IgG receptor IIa)
    |
    BI-1808
    almost6years
    [VIRTUAL] Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists (AACR-II 2020)
    In addition, the two antibodies similarly modulated the tumor myeloid content. Based on careful MoA-characterization, two human lead candidate anti-TNFR2 antibodies are being developed for treatment of solid cancer; BI-1808, a ligand-blocking T reg depleting antibody and BI-1910, a TNFR2 agonist.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    BI-1808 • BI-1910